<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-title>BMC Infectious Diseases</journal-title><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">15725345</article-id><article-id pub-id-type="pmc">PMC554105</article-id><article-id pub-id-type="publisher-id">1471-2334-5-9</article-id><article-id pub-id-type="doi">10.1186/1471-2334-5-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV)</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Uckun</surname><given-names>Fatih M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fatih_uckun@ih.org</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Rustamova</surname><given-names>Larisa</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>Lrustamova@briem.ac.by</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Vassilev</surname><given-names>Alexei O</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>avassilev@ih.org</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Tibbles</surname><given-names>Heather E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>htibbles@ih.org</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Petkevich</surname><given-names>Alexander S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>asp@briem.ac.by</email></contrib></contrib-group><aff id="I1"><label>1</label>Parker Hughes Center for Clinical Immunology, St. Paul, MN 55113, USA</aff><aff id="I2"><label>2</label>Research Institute for Epidemiology and Microbiology, 220050 MINSK, Belarus</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>22</day><month>2</month><year>2005</year></pub-date><volume>5</volume><fpage>9</fpage><lpage>9</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/5/9"/><history><date date-type="received"><day>25</day><month>6</month><year>2004</year></date><date date-type="accepted"><day>22</day><month>2</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Uckun et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Uckun et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Uckun
               M
               Fatih
               
               fatih_uckun@ih.org
            </dc:author><dc:title>
            CNS activity of Pokeweed Anti-viral Protein (PAP) in mice infected with Lymphocytic Choriomeningitis Virus (LCMV)
         </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>BMC Infectious Diseases 5(1): 9-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2334(2005)5:1&#x0003c;9&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2334</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Others and we have previously described the potent <italic>in vivo </italic>and <italic>in vitro </italic>activity of the broad-spectrum antiviral agent PAP (Pokeweed antiviral protein) against a wide range of viruses. The purpose of the present study was to further elucidate the anti-viral spectrum of PAP by examining its effects on the survival of mice challenged with lymphocytic choriomeningitis virus (LCMV).</p></sec><sec sec-type="methods"><title>Methods</title><p>We examined the therapeutic effect of PAP in CBA mice inoculated with intracerebral injections of the WE54 strain of LCMV at a 1000 PFU dose level that is lethal to 100% of mice within 7&#x02013;9 days. Mice were treated either with vehicle or PAP administered intraperitoneally 24 hours prior to, 1 hour prior to and 24 hours, 48 hours 72 hours and 96 hours after virus inoculation.</p></sec><sec><title>Results</title><p>PAP exhibits significant <italic>in vivo </italic>anti- LCMV activity in mice challenged intracerebrally with an otherwise invariably fatal dose of LCMV. At non-toxic dose levels, PAP significantly prolonged survival in the absence of the majority of disease-associated symptoms. The median survival time of PAP-treated mice was &#x0003e;21 days as opposed to 7 days median survival for the control (p = 0.0069).</p></sec><sec><title>Conclusion</title><p>Our results presented herein provide unprecedented experimental evidence that PAP exhibits antiviral activity in the CNS of LCMV-infected mice.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The broad-spectrum anti-viral agent PAP (Pokeweed antiviral protein) [<xref ref-type="bibr" rid="B1">1</xref>] is a well-characterized 29-kDa plant-derived ribosome-inactivating protein (RIP) isolated from Phytolacca americana [<xref ref-type="bibr" rid="B2">2</xref>]. The anti-viral activity of PAP has been described against a wide range of viruses, including HIV-1, herpes simplex virus, cytomegalovirus, influenza virus and polio virus [<xref ref-type="bibr" rid="B2">2</xref>] (For the most recent review, please see: [<xref ref-type="bibr" rid="B3">3</xref>]). The activity of PAP is attributed to its ability to inhibit protein synthesis by catalytically cleaving a specific adenine base from the highly conserved alpha-sarcin/ricin loop (SRL) of the large ribosomal RNA [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>] as well as from viral RNA[<xref ref-type="bibr" rid="B3">3</xref>]. The potent anti-HIV activity of PAP at nanomolar ranges taken together with the relative ease of large scale purification has led to the clinical use of PAP [<xref ref-type="bibr" rid="B2">2</xref>]. Since 1985, our group has studied the multifunctional efficacy of this potent agent [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B42">42</xref>].</p><p>The purpose of the present study was to further elucidate the anti-viral spectrum of PAP by examining its effects on survival of mice challenged with intracerebral inoculations of lymphocytic choriomeningitis virus (LCMV). LCMV is a rodent-borne arena virus that can result in persistent neuronal infection on mice [<xref ref-type="bibr" rid="B43">43</xref>,<xref ref-type="bibr" rid="B44">44</xref>]. Alpha-Dystroglycan (alpha-DG) was recently identified as a receptor for LCMV as well as for several other arena viruses including Lassa fever virus [<xref ref-type="bibr" rid="B45">45</xref>]. The binding affinity of LCMV to alpha-DG determines viral tropism and the outcome of infection in mice [<xref ref-type="bibr" rid="B46">46</xref>]. LCMV has also been associated with both postnatal and intrauterine human disease. Infection in man is acquired after inhalation, ingestion or direct contact with virus found in the urine, feces and saliva of infected mice, hamsters and guinea pigs. Congenital LCMV infection is a significant, often unrecognized cause of chorioretinitis, hydrocephalus, microcephaly or macrocelphaly as well as mental retardation. Acquired LCMV infection, asymptomatic in approximately one third of individuals, is productive of central nervous system manifestations in one half of the remaining cases. Aseptic meningitis or meningoenceophalitis are the predominant syndromes, although transverse myelitis, a Guillain-Barre-type syndrome, as well as transient and permanent acquired hydrocephalus have also been reported [<xref ref-type="bibr" rid="B47">47</xref>].</p><p>In the present study, we describe the significant efficacy of the highly stable, potent and broad-spectrum anti-viral agent PAP in a murine model of LCMV. Our results presented herein provide unprecedented experimental evidence that PAP exhibits antiviral activity in the CNS of LCMV-infected mice.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Purification of PAP</title><p>PAP was purified from spring leaves of the pokeweed plant, <italic>P. americanca</italic>, in four steps [<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B38">38</xref>]. Briefly, spring leaves were homogenized in a neutral pH buffer and centrifuged to sediment the remaining cellular fragments. The supernatant was fractionated between 60&#x02013;90% saturation of ammonium sulfate and the precipitate dialyzed against a low-ionic strength pH 7.5 buffer. The solution was passed through a DEAE cellulose column and the PAP-containing flow-through fraction was then applied to a cation exchange resin S-Sepharose column. The adsorbed PAP was eluted in a linear KCl gradient. The protein peak which eluted at 0.12 KCl was taken as PAP. This fraction was dialyzed extensively against water and lyophilized for storage at -20&#x000b0;C. The procedure resulted in homogeneous PAP, with a purity of &#x0003e;99% as measured by both SDS -12% PAGE and analytical cation- exchange high-performance liquid chromatography. Purified PAP induced concentration-dependent inhibition of HIV-1 replication in normal human peripheral blood mononuclear cells infected with the HIV-1 strain HTLV<sub>IIIB </sub>with an IC<sub>50 </sub>p24 of 14 &#x000b1; 2 nM.</p></sec><sec><title>Animal infection</title><p>Animal infection was performed in an appropriate Animal BioSafety Level-3 Laboratory (ABL-3) at BRIEM (Research Institute for Epidemiology and Microbiology, MINSK, Belarus) with the technician wearing appropriate facility clothing. The culture was thawed in a water bath at 37&#x000b0;C and then diluted in normal saline to achieve the required concentration. In this study, all mice were challenged with 1000 PFU which is 100-times higher than the LD<sub>50</sub> dose. Each group of animals was placed in a separate cage.</p></sec><sec><title>LCMV model</title><p>Three week old CBA mice were intracerebrally infected with 1000 PFU of WE54 strain of LCMV that resulted in lethality of 100% of control (non-treated) animals in 6&#x02013;8 days after infection. Control animals were given physiologic salt solution as a placebo instead of the compound. In general, for non-treated animals, clinical signs of the disease manifested on the 5<sup>th </sup>and 7<sup>th </sup>days by presenting: weight loss, immobility, disheveled hair, convulsions, severe decubitus paralysis and death. All subjective measurement of decreased mobility and scruffy fur were done in a blinded fashion as not to influence the results. The protective properties of the experimental anti-viral drugs were assessed by using the following treatment-preventative regimen: Mice were treated either with vehicle (n = 20) or PAP (n = 10) (0.25 mg/kg) administered intraperitoneally 24 hours prior to, 1 hour prior to, and 24 hours, 48 hours, 72 hours, and 96 hours after virus inoculation. Mice were then observed for 21-days post infection. The protective effect of the experimental anti-viral drugs was evaluated according to the rise of the survival rate and prolongation of mean life of the experimental animals as compared with the control animals.</p></sec><sec><title>Statistical analysis</title><p>Statistical significance was determined using the Kaplan Meier Log-Rank test.</p></sec></sec><sec><title>Results</title><p>In order to evaluate the anti-LCMV activity of PAP, mice were inoculated with intracerebral injections of LCMV at a dose level that is lethal to 100% of mice within 6&#x02013;8 days. Mice were treated either with vehicle or PAP as described in the methods section. Of the 20 control mice, 3 died on day 1 immediately after intracerebral injection due to accidental brain injury and are excluded from the data analysis. All 17 of the remaining control mice developed clinical signs of LCMV infection between day 4 and 6, including weight loss, disheveled hair, decreased mobility and paralysis (Table <xref ref-type="table" rid="T1">1</xref>). All control mice developed seizures between day 5 and day7 and died between day 6 and day 8 with a median survival of 7 days (Table <xref ref-type="table" rid="T1">1</xref>, Figure <xref ref-type="fig" rid="F1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Anti-LCMV activity of PAP in CBA mice</p></caption><table frame="hsides" rules="groups"><tbody><tr><td></td><td></td><td></td><td align="center" colspan="3"><bold>Disease Unset</bold></td></tr><tr><td></td><td></td><td></td><td align="center" colspan="3"><bold>Days after inoculation with LCM Virus</bold></td></tr><tr><td></td><td></td><td></td><td colspan="3"><hr></hr></td></tr><tr><td></td><td align="center"><bold>Survival (days)</bold></td><td align="center"><bold>Weight loss (grams)</bold></td><td align="center"><bold>Decreased mobility</bold></td><td align="center"><bold>Convulsions</bold></td><td align="center"><bold>Hair disheveled</bold></td></tr><tr><td></td><td colspan="5"><hr></hr></td></tr><tr><td align="left"><bold>Vehicle</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #1*</td><td align="center">&#x0003c;&#x0003c;1</td><td align="center">NA</td><td align="center">0</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #2*</td><td align="center">&#x0003c;&#x0003c;1</td><td align="center">NA</td><td align="center">0</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #3*</td><td align="center">&#x0003c;&#x0003c;1</td><td align="center">NA</td><td align="center">0</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #4</td><td align="center">6</td><td align="center">1.5</td><td align="center">4.5</td><td align="center">5.5</td><td align="center">4.5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #5</td><td align="center">6</td><td align="center">2</td><td align="center">4.5</td><td align="center">5.5</td><td align="center">4.5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #6</td><td align="center">7</td><td align="center">2</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #7</td><td align="center">7</td><td align="center">1.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #8</td><td align="center">7</td><td align="center">2.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #9</td><td align="center">7</td><td align="center">4.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #10</td><td align="center">7</td><td align="center">4.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #11</td><td align="center">7</td><td align="center">4.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #12</td><td align="center">8</td><td align="center">2</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #13</td><td align="center">8</td><td align="center">2.5</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #14</td><td align="center">8</td><td align="center">1</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #15</td><td align="center">8</td><td align="center">1.5</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #16</td><td align="center">8</td><td align="center">2</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #17</td><td align="center">8</td><td align="center">2</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #18</td><td align="center">7</td><td align="center">1.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #19</td><td align="center">8</td><td align="center">2</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #20</td><td align="center">8</td><td align="center">1.5</td><td align="center">6</td><td align="center">7</td><td align="center">6</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>PAP 0.25 mg/kg</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #1</td><td align="center">&#x0003c;&#x0003c;1</td><td align="center">NA</td><td align="center">NA</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #2</td><td align="center">&#x0003c;&#x0003c;1</td><td align="center">NA</td><td align="center">NA</td><td align="center">NA</td><td align="center">NA</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #3</td><td align="center">6</td><td align="center">1</td><td align="center">4.5</td><td align="center">5.5</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #4</td><td align="center">7</td><td align="center">1.5</td><td align="center">5</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #5</td><td align="center">8</td><td align="center">1.5</td><td align="center">6</td><td align="center">7</td><td align="center">5.5</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #6</td><td align="center">21</td><td align="center">0</td><td align="center">10</td><td align="center">NO</td><td align="center">NO</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #7</td><td align="center">21</td><td align="center">0</td><td align="center">10</td><td align="center">NO</td><td align="center">NO</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #8</td><td align="center">21</td><td align="center">0</td><td align="center">10</td><td align="center">NO</td><td align="center">NO</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #9</td><td align="center">21</td><td align="center">0</td><td align="center">10</td><td align="center">NO</td><td align="center">NO</td></tr><tr><td align="left">&#x02003;&#x02003;Mouse #10</td><td align="center">21</td><td align="center">0</td><td align="center">10</td><td align="center">NO</td><td align="center">NO</td></tr></tbody></table><table-wrap-foot><p>*Mouse died after intracerebral injection; NA = not applicable, NO = not observed</p></table-wrap-foot></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Protective Activity of PAP in CBA Mice Challenged with LCM Virus</bold>. CBA mice were inoculated with intracerebral injections of the WE54 strain of LCMV at a 1000 PFU dose level that is lethal to 100% of mice within 7&#x02013;9 days. Mice were treated either with vehicle or PAP administered intraperitoneally 24 hours prior to, 1 hour prior to and 24 hours, 48 hours 72 hours and 96 hours after virus inoculation. Mice were then observed twice daily for 21 days for morbidity and mortality. (<italic>Top</italic>) Shown are representative survival curves detailing the cumulative proportions (%) of mice surviving after virus inoculation. See Table 1 for more detailed information of the treatment outcome. (<italic>Bottom</italic>) Shown is Kaplan-Meir life-table analysis and statistical comparison using the log-rank test.</p></caption><graphic xlink:href="1471-2334-5-9-1"/></fig><p>Of the 10 mice treated with the broad-spectrum antiviral agent pokeweed antiviral protein (PAP), 2 died on day 1 immediately after intracerebral injection due to accidental brain injury and are invaluable. Five of the remaining 8 mice (62.5%) treated with PAP remained alive &#x0003e; 21 days post-LCMV inoculation <bold>(median survival &#x0003e;21 days, p = 0.0069) </bold>(Table <xref ref-type="table" rid="T1">1</xref>, Figure <xref ref-type="fig" rid="F1">1</xref>). These mice exhibited no LCMV infection-related weight loss or convulsions and showed no signs of scruffy fur. A significant improvement in mobility was also noted. Thus, PAP exhibited significant <italic>in vivo </italic>anti-LCMV activity in mice challenged intracerebrally with an otherwise invariably fatal dose of LCMV.</p></sec><sec><title>Discussion</title><p>In the present study, we describe the significant efficacy of the highly stable, potent and broad-spectrum anti-viral agent PAP in a murine model of LCMV. Our results presented herein provide unprecedented experimental evidence that PAP exhibits antiviral activity in the CNS of LCMV-infected mice. Future studies will examine the therapeutic activity of PAP against LCMV in post-challenge settings. As PAP is well described as an HIV agent, this observation is also relevant as HIV-1 infects the central nervous system (CNS) and it has been feared that the CNS may be a sanctuary site where HIV-1 could hide and continue to replicate despite otherwise effective antiretroviral treatment [<xref ref-type="bibr" rid="B48">48</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. Antiretroviral therapy of HIV-infected children is associated with a decline in CSF HIV RNA and an improvement in neurological status. The development of genotypic mutations was different in CSF and plasma, suggesting discordant viral evolution. These results suggest that antiretroviral treatment in children should include agents with activity in the CNS [<xref ref-type="bibr" rid="B50">50</xref>]. While these results suggest that PAP crosses the blood brain barrier and may therefore be beneficial in other viral infections affecting CNS, they need to be interpreted with due caution for HIV infections involving the CNS since LCMV affects leptomeninges while HIV affects neurons. In future studies, we must also consider the possibility that PAP penetrates the blood brain barrier only when the latter is impaired by the intracerebral administration of the virus. If this is the case, PAP may not be useful in pre-challenge prophylaxis against LCMV-mediated CNS infection. While these results support the notion that the antiviral activity spectrum of PAP covers LCMV as well, an immunomodulatory effect of PAP may also contribute to the observed prophylactic efficacy of PAP against LCMV.</p><p>Cases of LCMV infections have been reported in Europe, the Americas, Australia, and Japan. According to the Center for Disease Control, currently there is no specific drug therapy for LCMV. Although the anti-viral agent ribavirin is effective against LCMV in vitro, there is no established evidence to support its use for treatment of LCMV in humans [<xref ref-type="bibr" rid="B51">51</xref>].</p><p>The anti-viral activity of PAP has been described against numerous pathogenic viruses, which included poliovirus, HIV-1, herpes simplex virus, cytomegalovirus, influenza virus and now, the negative-strand RNA virus Lymphocytic choriomeningitis virus. The ability of PAP to inhibit viral protein synthesis and depurinate viral RNA and DNA [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>] as well as capped rRNA and mRNAs [<xref ref-type="bibr" rid="B52">52</xref>] and its ability to inhibit ribosomal frame shifting and retransposition, make it and ideal candidate for anti-viral strategies.</p></sec><sec><title>Conclusion</title><p>Treatment of CBA mice with the broad-spectrum anti-viral agent, PAP significantly improved the probability of survival following the LCMV challenge and decreased overall LCMV-related symptoms. The ability of PAP to exhibit anti-viral activity within the central nervous system is also encouraging within the framework of potential HIV-treatment. We have recently described the rational design and engineering of several recombinant PAP mutants with superior anti-HIV activity [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. In our future studies, we plan to describe the potential anti-LCMV activity of these PAP mutants as well as optimizing the prophylactic and post-exposure treatment regimens. In addition, it will be important to determine if PAP or PAP mutants have activity against other viruses associated with lethal viral hemorrhagic fevers and/or encephalomyelitis, such as the Ebola viruses of the Filoviridae family [<xref ref-type="bibr" rid="B53">53</xref>-<xref ref-type="bibr" rid="B56">56</xref>].</p></sec><sec><title>List of abbreviations</title><p>LCMV: Lymphocytic choriomeningitis virus</p><p>PAP: Pokeweed anti-viral protein</p><p>HIV and FIV: Human and Feline immunodeficiency virus, respectively</p></sec><sec><title>Competing interests</title><p>FMU is listed as an inventor on a number of PAP patents which are owned by PHI. FMU, AV and HET are salaried employees at PHI. PHI is a non-profit public charity.</p></sec><sec><title>Authors' contributions</title><p>FMU designed the research project. LR, AP &#x00026; LT conducted the Lassa experiments. FMU &#x00026; AV provided PAP and coordinated the Lassa experiments with LR, AP and LT. FMU and HT wrote the manuscript. All authors read and approved manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/5/9/prepub"/></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Pokeweed antiviral protein: ribosome inactivation and therapeutic applications</article-title><source>Pharmacol Ther</source><year>1992</year><volume>55</volume><fpage>279</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">1492120</pub-id><pub-id pub-id-type="doi">10.1016/0163-7258(92)90053-3</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Cruz</surname><given-names>OJ</given-names></name><name><surname>Waurzyniakt</surname><given-names>B</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>A 13-week subchronic intravaginal toxicity study of pokeweed antiviral protein in mice</article-title><source>Phytomedicine</source><year>2004</year><volume>11</volume><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">15185849</pub-id><pub-id pub-id-type="doi">10.1078/0944711041495209</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>BA</given-names></name><name><surname>Turner</surname><given-names>NE</given-names></name></person-group><article-title>Antiviral activity of ribosome inactivating proteins in medicine</article-title><source>Mini Rev Med Chem</source><year>2004</year><volume>4</volume><fpage>523</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">15180509</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Ozer</surname><given-names>Z</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Active center cleft residues of pokeweed antiviral protein mediate its high-affinity binding to the ribosomal protein L3</article-title><source>Biochemistry</source><year>2001</year><volume>40</volume><fpage>9104</fpage><lpage>9114</lpage><pub-id pub-id-type="pmid">11478877</pub-id><pub-id pub-id-type="doi">10.1021/bi002851p</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>High resolution X-ray structure of potent anti-HIV pokeweed antiviral protein-III</article-title><source>Biochem Pharmacol</source><year>2003</year><volume>65</volume><fpage>1709</fpage><lpage>1717</lpage><pub-id pub-id-type="pmid">12754107</pub-id><pub-id pub-id-type="doi">10.1016/S0006-2952(03)00144-8</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Pendergrass</surname><given-names>S</given-names></name><name><surname>Ozer</surname><given-names>Z</given-names></name><name><surname>Waurzyniak</surname><given-names>B</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name></person-group><article-title>Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activity</article-title><source>Antimicrob Agents Chemother</source><year>2003</year><volume>47</volume><fpage>1052</fpage><lpage>1061</lpage><pub-id pub-id-type="pmid">12604541</pub-id><pub-id pub-id-type="doi">10.1128/AAC.47.3.1052-1061.2003</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Binding interactions between the active center cleft of recombinant pokeweed antiviral protein and the alpha-sarcin/ricin stem loop of ribosomal RNA</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>24075</fpage><lpage>24081</lpage><pub-id pub-id-type="pmid">11313342</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M011406200</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D'Cruz</surname><given-names>OJ</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Pokeweed antiviral protein: a potential nonspermicidal prophylactic antiviral agent</article-title><source>Fertil Steril</source><year>2001</year><volume>75</volume><fpage>106</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">11163824</pub-id><pub-id pub-id-type="doi">10.1016/S0015-0282(00)01665-4</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Mao</surname><given-names>C</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>X-ray crystallographic analysis of pokeweed antiviral protein-II after reductive methylation of lysine residues</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>275</volume><fpage>549</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">10964701</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2000.3329</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Doumbia</surname><given-names>SO</given-names></name><name><surname>Engstrom</surname><given-names>CR</given-names></name><name><surname>Pendergras</surname><given-names>SL</given-names></name><name><surname>Maher</surname><given-names>DL</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Expression of biologically active recombinant pokeweed antiviral protein in methylotrophic yeast Pichia pastoris</article-title><source>Protein Expr Purif</source><year>2000</year><volume>18</volume><fpage>193</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">10686150</pub-id><pub-id pub-id-type="doi">10.1006/prep.1999.1181</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Pugmire</surname><given-names>MJ</given-names></name><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Modeling and alanine scanning mutagenesis studies of recombinant pokeweed antiviral protein</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>3382</fpage><lpage>3390</lpage><pub-id pub-id-type="pmid">10652330</pub-id><pub-id pub-id-type="doi">10.1074/jbc.275.5.3382</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Venkatachalam</surname><given-names>TK</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>X-ray crystallographic analysis of the structural basis for the interaction of pokeweed antiviral protein with guanine residues of ribosomal RNA</article-title><source>Protein Sci</source><year>1999</year><volume>8</volume><fpage>2399</fpage><lpage>2405</lpage><pub-id pub-id-type="pmid">10595542</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Bellomy</surname><given-names>K</given-names></name><name><surname>O'Neill</surname><given-names>K</given-names></name><name><surname>Messinger</surname><given-names>Y</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>CL</given-names></name></person-group><article-title>Toxicity, biological activity, and pharmacokinetics of TXU (anti-CD7)-pokeweed antiviral protein in chimpanzees and adult patients infected with human immunodeficiency virus</article-title><source>J Pharmacol Exp Ther</source><year>1999</year><volume>291</volume><fpage>1301</fpage><lpage>1307</lpage><pub-id pub-id-type="pmid">10565855</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>X-ray crystallographic analysis of the structural basis for the interactions of pokeweed antiviral protein with its active site inhibitor and ribosomal RNA substrate analogs</article-title><source>Protein Sci</source><year>1999</year><volume>8</volume><fpage>1765</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">10493577</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Kurinov</surname><given-names>IV</given-names></name><name><surname>Venkatachalam</surname><given-names>TK</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Deguanylation of human immunodeficiency virus (HIV-1) RNA by recombinant pokeweed antiviral protein</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>263</volume><fpage>419</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">10491308</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.1335</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Engstrom</surname><given-names>CR</given-names></name><name><surname>Denton</surname><given-names>TJ</given-names></name><name><surname>Engen</surname><given-names>LA</given-names></name><name><surname>Kourinov</surname><given-names>I</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>High-level expression and purification of biologically active recombinant pokeweed antiviral protein</article-title><source>Protein Expr Purif</source><year>1999</year><volume>16</volume><fpage>359</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">10419833</pub-id><pub-id pub-id-type="doi">10.1006/prep.1999.1084</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajamohan</surname><given-names>F</given-names></name><name><surname>Venkatachalam</surname><given-names>TK</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Pokeweed antiviral protein isoforms PAP-I, PAP-II, and PAP-III depurinate RNA of human immunodeficiency virus (HIV)-1</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>260</volume><fpage>453</fpage><lpage>458</lpage><pub-id pub-id-type="pmid">10403789</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.0922</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waurzyniak</surname><given-names>B</given-names></name><name><surname>Schneider</surname><given-names>EA</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Yanishevski</surname><given-names>Y</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Wendorf</surname><given-names>H</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Messinger</surname><given-names>Y</given-names></name><name><surname>Ek</surname><given-names>O</given-names></name><name><surname>Zeren</surname><given-names>T</given-names></name><name><surname>Langlie</surname><given-names>MC</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>881</fpage><lpage>890</lpage><pub-id pub-id-type="pmid">9815763</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Yanishevski</surname><given-names>Y</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Waurzyniak</surname><given-names>B</given-names></name><name><surname>Messinger</surname><given-names>Y</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Lisowski</surname><given-names>EA</given-names></name><name><surname>Ek</surname><given-names>O</given-names></name><name><surname>Zeren</surname><given-names>T</given-names></name><name><surname>Wendorf</surname><given-names>H</given-names></name><name><surname>Langlie</surname><given-names>MC</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Fuller</surname><given-names>GB</given-names></name><name><surname>Evans</surname><given-names>W</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name></person-group><article-title>Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys</article-title><source>Clin Cancer Res</source><year>1997</year><volume>3</volume><fpage>325</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">9815689</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ek</surname><given-names>O</given-names></name><name><surname>Waurzyniak</surname><given-names>B</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Antitumor activity of TP3(anti- p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>1641</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">9676838</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Dibirdik</surname><given-names>I</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Langlie</surname><given-names>MC</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name></person-group><article-title>TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus</article-title><source>Antimicrob Agents Chemother</source><year>1998</year><volume>42</volume><fpage>383</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">9527790</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Jun</surname><given-names>X</given-names></name><name><surname>Clementson</surname><given-names>D</given-names></name><name><surname>Donelson</surname><given-names>R</given-names></name><name><surname>Sicheneder</surname><given-names>A</given-names></name><name><surname>Hoffman</surname><given-names>N</given-names></name><name><surname>Bell</surname><given-names>K</given-names></name><name><surname>Sarquis</surname><given-names>M</given-names></name><name><surname>Langlie</surname><given-names>MC</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials</article-title><source>Leuk Lymphoma</source><year>1997</year><volume>27</volume><fpage>275</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">9402326</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zoubenko</surname><given-names>O</given-names></name><name><surname>Uckun</surname><given-names>F</given-names></name><name><surname>Hur</surname><given-names>Y</given-names></name><name><surname>Chet</surname><given-names>I</given-names></name><name><surname>Turner</surname><given-names>N</given-names></name></person-group><article-title>Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants</article-title><source>Nat Biotechnol</source><year>1997</year><volume>15</volume><fpage>992</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">9335052</pub-id><pub-id pub-id-type="doi">10.1038/nbt1097-992</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Wendorf</surname><given-names>HR</given-names></name><name><surname>Schneider</surname><given-names>EA</given-names></name><name><surname>Covalciuc</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Clementson</surname><given-names>D</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin</article-title><source>Leuk Lymphoma</source><year>1996</year><volume>22</volume><fpage>61</fpage><lpage>70</lpage><comment>follow 186, color plate II-V</comment><pub-id pub-id-type="pmid">8724529</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waddick</surname><given-names>KG</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Chandan-Langlie</surname><given-names>M</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Tumer</surname><given-names>N</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells</article-title><source>Blood</source><year>1995</year><volume>86</volume><fpage>4228</fpage><lpage>4233</lpage><pub-id pub-id-type="pmid">7492781</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hur</surname><given-names>Y</given-names></name><name><surname>Hwang</surname><given-names>DJ</given-names></name><name><surname>Zoubenko</surname><given-names>O</given-names></name><name><surname>Coetzer</surname><given-names>C</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Tumer</surname><given-names>NE</given-names></name></person-group><article-title>Isolation and characterization of pokeweed antiviral protein mutations in Saccharomyces cerevisiae: identification of residues important for toxicity</article-title><source>Proc Natl Acad Sci U S A</source><year>1995</year><volume>92</volume><fpage>8448</fpage><lpage>8452</lpage><pub-id pub-id-type="pmid">7667309</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Yanishevski</surname><given-names>Y</given-names></name><name><surname>Masson</surname><given-names>E</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Evans</surname><given-names>WE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD 19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody molecule</article-title><source>Leuk Lymphoma</source><year>1995</year><volume>18</volume><fpage>93</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">8580835</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Simon</surname><given-names>J</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin</article-title><source>Blood</source><year>1995</year><volume>85</volume><fpage>2537</fpage><lpage>2545</lpage><pub-id pub-id-type="pmid">7537120</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>PM</given-names></name><name><surname>Meyers</surname><given-names>DE</given-names></name><name><surname>Hasz</surname><given-names>DE</given-names></name><name><surname>Covalcuic</surname><given-names>K</given-names></name><name><surname>Saltzman</surname><given-names>D</given-names></name><name><surname>Khanna</surname><given-names>C</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein</article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>1321</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">7882330</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Erice</surname><given-names>A</given-names></name><name><surname>Balfour</surname><given-names>HH</given-names><suffix>Jr</suffix></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Leske</surname><given-names>VL</given-names></name><name><surname>Sannerud</surname><given-names>KJ</given-names></name><name><surname>Kuebelbeck</surname><given-names>V</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein</article-title><source>Antimicrob Agents Chemother</source><year>1993</year><volume>37</volume><fpage>835</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">8494381</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Kuebelbeck</surname><given-names>VM</given-names></name><name><surname>Finnegan</surname><given-names>D</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Houston</surname><given-names>LL</given-names></name></person-group><article-title>Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin</article-title><source>Leuk Lymphoma</source><year>1993</year><volume>9</volume><fpage>459</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">7687916</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Finnegan</surname><given-names>D</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency</article-title><source>Leukemia</source><year>1993</year><volume>7</volume><fpage>298</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">7678882</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>B</given-names></name><name><surname>Kersey</surname><given-names>JH</given-names></name><name><surname>Jaszcz</surname><given-names>WB</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>DP</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide</article-title><source>Leukemia</source><year>1993</year><volume>7</volume><fpage>290</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">7678881</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Haissig</surname><given-names>S</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Fidler</surname><given-names>P</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Kuebelbeck</surname><given-names>V</given-names></name><name><surname>Weisdorf</surname><given-names>D</given-names></name><name><surname>Gajl-Peczalska</surname><given-names>K</given-names></name><name><surname>Kersey</surname><given-names>JH</given-names></name><name><surname>Ramsay</surname><given-names>NK</given-names></name></person-group><article-title>Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD 19 pan-B-cell immunotoxin containing pokeweed antiviral protein</article-title><source>Blood</source><year>1992</year><volume>79</volume><fpage>3369</fpage><lpage>3379</lpage><pub-id pub-id-type="pmid">1375851</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Finnegan</surname><given-names>D</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Manivel</surname><given-names>C</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name></person-group><article-title>Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide</article-title><source>Blood</source><year>1992</year><volume>79</volume><fpage>3116</fpage><lpage>3129</lpage><pub-id pub-id-type="pmid">1375841</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Finnegan</surname><given-names>D</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Kuebelbeck</surname><given-names>V</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Houston</surname><given-names>LL</given-names></name></person-group><article-title>In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia</article-title><source>Blood</source><year>1992</year><volume>79</volume><fpage>2649</fpage><lpage>2661</lpage><pub-id pub-id-type="pmid">1375109</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Manivel</surname><given-names>C</given-names></name><name><surname>Arthur</surname><given-names>D</given-names></name><name><surname>Chelstrom</surname><given-names>LM</given-names></name><name><surname>Finnegan</surname><given-names>D</given-names></name><name><surname>Tuel-Ahlgren</surname><given-names>L</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Gunther</surname><given-names>R</given-names></name></person-group><article-title>In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency</article-title><source>Blood</source><year>1992</year><volume>79</volume><fpage>2201</fpage><lpage>2214</lpage><pub-id pub-id-type="pmid">1373967</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Irvin</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>Kuebelbeck</surname><given-names>VM</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials</article-title><source>J Immunol Methods</source><year>1991</year><volume>136</volume><fpage>221</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">1705571</pub-id><pub-id pub-id-type="doi">10.1016/0022-1759(91)90009-5</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zarling</surname><given-names>JM</given-names></name><name><surname>Moran</surname><given-names>PA</given-names></name><name><surname>Haffar</surname><given-names>O</given-names></name><name><surname>Diegel</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>DE</given-names></name><name><surname>Kuelbeck</surname><given-names>V</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name></person-group><article-title>Inhibition of HIV-1 replication in seropositive patients' CD4+ T-cells by pokeweed antiviral protein-monoclonal antibody conjugates</article-title><source>Int J Immunopharmacol</source><year>1991</year><volume>13</volume><fpage>63</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">1688086</pub-id><pub-id pub-id-type="doi">10.1016/0192-0561(91)90126-R</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Gajl-Peczalska</surname><given-names>KJ</given-names></name><name><surname>Kersey</surname><given-names>JH</given-names></name><name><surname>Houston</surname><given-names>LL</given-names></name><name><surname>Vallera</surname><given-names>DA</given-names></name></person-group><article-title>Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia</article-title><source>J Exp Med</source><year>1986</year><volume>163</volume><fpage>347</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">3511171</pub-id><pub-id pub-id-type="doi">10.1084/jem.163.2.347</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Houston</surname><given-names>LL</given-names></name></person-group><article-title>Anti-T cell immunotoxins containing pokeweed anti-viral protein: potential purging agents for human autologous bone marrow transplantation</article-title><source>J Immunol</source><year>1985</year><volume>135</volume><fpage>3616</fpage><lpage>3622</lpage><pub-id pub-id-type="pmid">3900212</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uckun</surname><given-names>FM</given-names></name><name><surname>Ramakrishnan</surname><given-names>S</given-names></name><name><surname>Houston</surname><given-names>LL</given-names></name></person-group><article-title>Ex vivo elimination of neoplastic T-cells from human marrow using an anti-Mr 41,000 protein immunotoxin: potentiation by ASTA Z 7557</article-title><source>Blut</source><year>1985</year><volume>50</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">3881146</pub-id><pub-id pub-id-type="doi">10.1007/BF00319765</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kappes</surname><given-names>DJ</given-names></name><name><surname>Lawrence</surname><given-names>DM</given-names></name><name><surname>Vaughn</surname><given-names>MM</given-names></name><name><surname>Dave</surname><given-names>VP</given-names></name><name><surname>Belman</surname><given-names>AR</given-names></name><name><surname>Rall</surname><given-names>GF</given-names></name></person-group><article-title>Protection of CD3 delta knockout mice from lymphocytic choriomeningitis virus-induced immunopathology: implications for viral neuroinvasion</article-title><source>Virology</source><year>2000</year><volume>269</volume><fpage>248</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">10753703</pub-id><pub-id pub-id-type="doi">10.1006/viro.2000.0224</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asensio</surname><given-names>VC</given-names></name><name><surname>Kincaid</surname><given-names>C</given-names></name><name><surname>Campbell</surname><given-names>IL</given-names></name></person-group><article-title>Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus</article-title><source>J Neurovirol</source><year>1999</year><volume>5</volume><fpage>65</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">10190692</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Henry</surname><given-names>MD</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Yamada</surname><given-names>H</given-names></name><name><surname>Elder</surname><given-names>JH</given-names></name><name><surname>Ravkov</surname><given-names>EV</given-names></name><name><surname>Nichol</surname><given-names>ST</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Campbell</surname><given-names>KP</given-names></name><name><surname>Oldstone</surname><given-names>MB</given-names></name></person-group><article-title>Identification of alpha dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus</article-title><source>Science</source><year>1998</year><volume>282</volume><fpage>2079</fpage><lpage>2081</lpage><pub-id pub-id-type="pmid">9851928</pub-id><pub-id pub-id-type="doi">10.1126/science.282.5396.2079</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smelt</surname><given-names>SC</given-names></name><name><surname>Borrow</surname><given-names>P</given-names></name><name><surname>Kunz</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Tishon</surname><given-names>A</given-names></name><name><surname>Lewicki</surname><given-names>H</given-names></name><name><surname>Campbell</surname><given-names>KP</given-names></name><name><surname>Oldstone</surname><given-names>MB</given-names></name></person-group><article-title>Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>448</fpage><lpage>457</lpage><pub-id pub-id-type="pmid">11119613</pub-id><pub-id pub-id-type="doi">10.1128/JVI.75.1.448-457.2001</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barton</surname><given-names>LL</given-names></name><name><surname>Hyndman</surname><given-names>NJ</given-names></name></person-group><article-title>Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen</article-title><source>Pediatrics</source><year>2000</year><volume>105</volume><fpage>E35</fpage><pub-id pub-id-type="pmid">10699137</pub-id><pub-id pub-id-type="doi">10.1542/peds.105.3.e35</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gisslen</surname><given-names>M</given-names></name><name><surname>Hagberg</surname><given-names>L</given-names></name></person-group><article-title>Antiretroviral treatment of central nervous system HIV-1 infection: a review</article-title><source>HIV Med</source><year>2001</year><volume>2</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">11737386</pub-id><pub-id pub-id-type="doi">10.1046/j.1468-1293.2001.00056.x</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mamidi</surname><given-names>A</given-names></name><name><surname>DeSimone</surname><given-names>JA</given-names></name><name><surname>Pomerantz</surname><given-names>RJ</given-names></name></person-group><article-title>Central nervous system infections in individuals with HIV-1 infection</article-title><source>J Neurovirol</source><year>2002</year><volume>8</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">12053271</pub-id><pub-id pub-id-type="doi">10.1080/13550280290049723</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCoig</surname><given-names>C</given-names></name><name><surname>Castrejon</surname><given-names>MM</given-names></name><name><surname>Castano</surname><given-names>E</given-names></name><name><surname>De Suman</surname><given-names>O</given-names></name><name><surname>Baez</surname><given-names>C</given-names></name><name><surname>Redondo</surname><given-names>W</given-names></name><name><surname>McClernon</surname><given-names>D</given-names></name><name><surname>Danehower</surname><given-names>S</given-names></name><name><surname>Lanier</surname><given-names>ER</given-names></name><name><surname>Richardson</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>A</given-names></name><name><surname>Hetherington</surname><given-names>S</given-names></name><name><surname>Saez-Llorens</surname><given-names>X</given-names></name><name><surname>Ramilo</surname><given-names>O</given-names></name></person-group><article-title>Effect of combination antiretroviral therapy on cerebrospinal fluid HIV RNA, HIV resistance, and clinical manifestations of encephalopathy</article-title><source>J Pediatr</source><year>2002</year><volume>141</volume><fpage>36</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">12091849</pub-id><pub-id pub-id-type="doi">10.1067/mpd.2002.125007</pub-id></citation></ref><ref id="B51"><citation citation-type="other"><article-title>Center for Disease Control (CDC) Special Pathogen Branch</article-title><ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/lcmv.htm"/></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hudak</surname><given-names>KA</given-names></name><name><surname>Bauman</surname><given-names>JD</given-names></name><name><surname>Turner</surname><given-names>NE</given-names></name></person-group><article-title>Pokeweed antiviral protein binds to the cap structure of eukaryotic mRNA and depurinates the mRNA downstream of the cap</article-title><source>Rna</source><year>2002</year><volume>8</volume><fpage>1148</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">12358434</pub-id><pub-id pub-id-type="doi">10.1017/S1355838202026638</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JP</given-names></name><name><surname>Cosgriff</surname><given-names>TM</given-names></name></person-group><article-title>Hemorrhagic fever virus-induced changes in hemostasis and vascular biology</article-title><source>Blood Coagul Fibrinolysis</source><year>2000</year><volume>11</volume><fpage>461</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">10937808</pub-id><pub-id pub-id-type="doi">10.1097/00001721-200007000-00010</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peterson</surname><given-names>AT</given-names></name><name><surname>Bauer</surname><given-names>JT</given-names></name><name><surname>Mills</surname><given-names>JN</given-names></name></person-group><article-title>Ecologic and geographic distribution of filovirus disease</article-title><source>Emerg Infect Dis</source><year>2004</year><volume>10</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15078595</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Schnittler</surname><given-names>HJ</given-names></name></person-group><article-title>Ebola virus: from discovery to vaccine</article-title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>677</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">12974482</pub-id><pub-id pub-id-type="doi">10.1038/nri1154</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>ZY</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group><article-title>Ebola virus pathogenesis: implications for vaccines and therapies</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>9733</fpage><lpage>9737</lpage><pub-id pub-id-type="pmid">12941881</pub-id><pub-id pub-id-type="doi">10.1128/JVI.77.18.9733-9737.2003</pub-id></citation></ref></ref-list></back></article>



